Targeted next-generation sequencing of circulating free DNA enables non-invasive tumor detection in myxoid liposarcomas

Mol Cancer. 2022 Feb 14;21(1):50. doi: 10.1186/s12943-022-01523-x.
No abstract available

Keywords: Circulating tumor DNA; Diagnostic biomarker, Intratumor heterogeneity; Liquid biopsy; Myxoid liposarcoma; Next-generation sequencing; Soft tissue sarcoma; Targeted sequencing; ctDNA.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Cell-Free Nucleic Acids* / genetics
  • DNA
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Liposarcoma, Myxoid* / diagnosis
  • Liposarcoma, Myxoid* / genetics
  • Liposarcoma, Myxoid* / pathology
  • Neoplasms*

Substances

  • Biomarkers, Tumor
  • Cell-Free Nucleic Acids
  • DNA